Parkinson's Vaccine Goes Into Phase I Clinical Trial
Tuesday, December 9, 2014 - 15:10
in Health & Medicine
A Parkinson's disease vaccine developed by the Austrian biotech company AFFiRiS AG is going into a Phase I trial clinical trial. The vaccine, called AFFITOPE® PD03A , targets a protein called alpha-Synuclein. The protein plays a key role in the onset and progression of Parkinson's as well as multiple system atrophy (MSA), an orphan disease. This vaccine has the potential to modify disease progression, rather than only symptomatic improvements available with current treatment strategies. read more